OCT
OCT · page 2
- Pharmaceutical
OCT Co-Founder Publishes Scathing Letter Accusing Directors of ‘Serious Governance & Management’ Failings Ahead of GM Vote to Oust Board
GAVIN Sathianathan, a founder member of Oxford Cannabinoid Technologies (OCT), published a bombshell letter to fellow investors last week laying bare the numerous reasons behind his call for the company’s board to be replaced.
- Pharmaceutical
EU Cannabis Stocks Review: OCT Board Accused of Serious Governance Issues by Co-Founder, Panaxia’s Debt Pile Hits Stock & More from Love Hemp
AS European Cannabis stocks continue their battle against external market forces, it has been internal battles which made the headlines this week.
- Pharmaceutical
Oxford Cannabinoid Technologies Says Data From Pre-Clinical Study of Leading Drug Candidate Shows Positive Results
OXFORD Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion pain market is pleased to announce positive results from a pre-clinical pain study for its lead compound, OCT461201, targeting the global Chemotherapy Induced Peripheral Neuropathy (“CIPN”) treatment market valued at US$1.61bn in 2020 and forecasted…
- Pharmaceutical
EU Cannabis Stocks Review: Love Hemp jumps 60%, OCT sees recovery & more from Cellular Goods, Chill Brands and MGC Pharma
On the 1-year anniversary of the first cannabis company to list on the London Stock Exchange, we examine the reaction to a number of significant announcements from some of the UK’s biggest cannabis players, making for an eventful week in the markets.
- Pharmaceutical
Oxford Cannabinoid Technologies Welcomes Imperial Brands Director to Board and Appoints New Chair
Richard Guy Hathaway has been appointed to the Board as a Non-Executive Director, as a representative of Imperial Brands Ventures Limited (“Imperial”), with effect from 1 February 2022.
- Pharmaceutical
Oxford Cannabinoid Technologies Signs New Agreement With Stemtech
OCT believes Stemtech’s technology provides an in vitro translational model that will better predict results in humans.
